EVALUATION OF THE EFFECTIVENESS OF THE ADDITIONAL RISK MINIMISATION MEASURES FOR GLOFITAMAB: A PASS SURVEY AMONG HEALTHCARE PROFESSIONALS IN EUROPEAN COUNTRIES

08/01/2026
12/01/2026
EU PAS number:
EUPAS1000000863
Study
Planned
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

Protocol - BO44309 - COLUMVI - v3 - redacted.pdf

English (1.03 MB - PDF) View document
Study results
Study report
Other information